Viltolarsen
- TRADE NAME: Viltepso (Nippon Shinyaku)
- INDICATIONS: Duchenne muscular dystrophy
- CLASS: Antisense oligomer, Antisense oligonucleotide
- HALF-LIFE: 2.5 hours
FDA APPROVAL DATE: 08/12/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Based on in vitro data, viltolarsen has a low potential for drug-drug interactions with major CYP enzymes and drug transporters in humans.
No human or animal data available to assess use during pregnancy.
Kidney toxicity was observed in animals who received viltolarsen. Although kidney toxicity was not observed in the clinical studies with viltolarsen, the clinical experience with viltolarsen is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking viltolarsen.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 04/27/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
